Clinical Outcomes After Definitive Treatment of Soft Tissue Sarcoma of the Hand: A Retrospective Cohort Study of 109 Patients

被引:0
|
作者
Chapman, Talia R. [1 ]
Lavery, Jessica A. [2 ]
Nolan, John E. [1 ,3 ]
Athanasian, Edward A. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY USA
[3] Northwell Hlth, Dept Surg, New Hyde Pk, NY USA
来源
关键词
Hand; recurrence; sarcoma; soft tissue sarcoma; surgical resection; COMPLICATIONS;
D O I
10.1016/j.jhsa.2024.05.003
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Purpose The purpose of this study was to provide updated data on oncologic outcomes following definitive surgical treatment of soft tissue sarcoma of the hand in a cohort of 109 patients, as well as to characterize risk factors for poor oncologic and functional outcomes. Methods We analyzed data from 109 consecutive patients who had definitive surgical treatment for soft tissue sarcoma of the hand performed between 1996 and 2019 by a single surgeon at a sarcoma center. Primary outcomes included functional outcome (assessed by Musculoskeletal Tumor Society scores), disease-free survival (DFS), and overall survival (OS). We compiled descriptive data and used a multivariable linear model to identify factors associated with functional outcomes. Kaplan-Meier methods were used to estimate 5and 10- year DFS and OS. Results Patients had a median age of 36 years at presentation. Median follow-up was 6.1 years among patients alive at the end of follow-up. The median Musculoskeletal Tumor Society score was 29; functional outcome was worse among patients with high-grade tumors or complications. Among the 107 patients who became disease-free, there were four local recurrences (one with metastasis), six distant recurrences, and one death without recurrence. All local recurrences were deep tumors (two myxofibrosarcoma and two myxoinflammatory fibrosarcoma). Estimated 5and 10-year DFS rates were 89% (95% confidence interval [CI]: 83% to 96%) and 88% (95% CI: 80% to 95%). There were seven deaths, and the estimated 5and 10-year OS rates were 95% (95% CI: 90% to 100%) and 92% (95% CI: 84% to 100%). Larger tumor size and higher stage at diagnosis were associated with shorter DFS and OS in univariable analyses; low event rates precluded multivariable analysis of survival. Conclusions Aggressive disease-specific surgical and multidisciplinary treatment can yield long DFS and OS, and good functional outcomes. However, complications and high-grade tumors are associated with worse functional scores.
引用
收藏
页码:867 / 874
页数:8
相关论文
共 50 条
  • [1] Clinical Outcomes for Patients With Soft Tissue Sarcoma of the Hand
    Puhaindran, Mark E.
    Rohde, Rachel S.
    Chou, Joanne
    Morris, Carol D.
    Athanasian, Edward A.
    CANCER, 2011, 117 (01) : 175 - 179
  • [2] A retrospective cohort study of treatment patterns among patients with metastatic soft tissue sarcoma in the US
    Villalobos, Victor M.
    Byfield, Stacey DaCosta
    Ghate, Sameer R.
    Adejoro, Oluwakayode
    CLINICAL SARCOMA RESEARCH, 2017, 7
  • [3] Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study
    Chung Ryul Oh
    Jung Yong Hong
    Jee Hung Kim
    Ji Sung Lee
    Hyo Song Kim
    Tae Won Kim
    Jin-Hee Ahn
    Jeong Eun Kim
    Targeted Oncology, 2020, 15 : 485 - 493
  • [4] Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study
    Oh, Chung Ryul
    Hong, Jung Yong
    Kim, Jee Hung
    Lee, Ji Sung
    Kim, Hyo Song
    Kim, Tae Won
    Ahn, Jin-Hee
    Kim, Jeong Eun
    TARGETED ONCOLOGY, 2020, 15 (04) : 485 - 493
  • [5] Clinical outcomes of radio-hyperthermo-chemotherapy for soft tissue sarcoma compared to a soft tissue sarcoma registry in Japan: a retrospective matched-pair cohort study
    Aiba, Hisaki
    Yamada, Satoshi
    Mizutani, Jun
    Yamamoto, Norio
    Okamoto, Hideki
    Hayashi, Katsuhiro
    Kimura, Hiroaki
    Takeuchi, Akihiko
    Miwa, Shinji
    Kawai, Akira
    Yoshimura, Kenichi
    Tsuchiya, Hiroyuki
    Otsuka, Takanobu
    CANCER MEDICINE, 2018, 7 (04): : 1560 - 1571
  • [6] Analysis of Clinical Outcomes of Patients with Soft Tissue Sarcoma
    Garg, Lokesh
    Pruthi, Manish
    Batra, Ullas
    Doval, D. C.
    Pasricha, Sunil
    Jaipuria, Jiten
    Virk, Jagandeep Singh
    Tiwari, Akshay
    INDIAN JOURNAL OF SURGICAL ONCOLOGY, 2022, 13 (03) : 518 - 524
  • [7] Analysis of Clinical Outcomes of Patients with Soft Tissue Sarcoma
    Lokesh Garg
    Manish Pruthi
    Ullas Batra
    D. C. Doval
    Sunil Pasricha
    Jiten Jaipuria
    Jagandeep Singh Virk
    Akshay Tiwari
    Indian Journal of Surgical Oncology, 2022, 13 : 518 - 524
  • [8] Trabectedin for inoperable or recurrent soft tissue sarcoma in adult patients: a retrospective cohort study
    Fernando A. Angarita
    Amanda J. Cannell
    Albiruni R. Abdul Razak
    Brendan C. Dickson
    Martin E. Blackstein
    BMC Cancer, 16
  • [9] Trabectedin for inoperable or recurrent soft tissue sarcoma in adult patients: a retrospective cohort study
    Angarita, Fernando A.
    Cannell, Amanda J.
    Razak, Albiruni R. Abdul
    Dickson, Brendan C.
    Blackstein, Martin E.
    BMC CANCER, 2016, 16
  • [10] Soft-tissue reconstruction after soft-tissue sarcoma resection: the clinical outcomes of 24 patients
    Hasegawa, Hideo
    Tsukamoto, Shinji
    Honoki, Kanya
    Shimizu, Takamasa
    Ferra, Lorenzo
    Errani, Costantino
    Sioutis, Spyros
    Mavrogenis, Andreas F.
    Tanaka, Yasuhito
    EUROPEAN JOURNAL OF ORTHOPAEDIC SURGERY AND TRAUMATOLOGY, 2022, 32 (01): : 1 - 10